Drug Type Recombinant protein |
Synonyms Haemostasis therapeutic, Haemostat topical, PeproStat + [2] |
Target |
Action stimulants |
Mechanism fibrin stimulants(Fibrin stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Blood Loss, Surgical | Phase 2 | South Korea | 05 Aug 2021 | |
Blood Coagulation Disorders | Phase 2 | Bosnia and Herzegovina | 31 Mar 2017 | |
Blood Coagulation Disorders | Phase 2 | Croatia | 31 Mar 2017 | |
Blood Coagulation Disorders | Phase 2 | Poland | 31 Mar 2017 | |
Blood Coagulation Disorders | Phase 2 | Serbia | 31 Mar 2017 | |
Blood Coagulation Disorders | Phase 2 | United Kingdom | 31 Mar 2017 | |
Hemorrhage | Phase 2 | Bosnia and Herzegovina | 31 Mar 2017 | |
Hemorrhage | Phase 2 | Croatia | 31 Mar 2017 | |
Hemorrhage | Phase 2 | Poland | 31 Mar 2017 | |
Hemorrhage | Phase 2 | Serbia | 31 Mar 2017 |